http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
갱년기 골다공증 환자의 HRT와 Alendronate 1년 병합치료 효과
오한진(Han Jin Oh),임창훈(Chang Hun Lim),정호연(Ho Yeon Chung),한기옥(Ki Ok Han),장학철(Hak Chul Jang),윤현규(Hyun Koo Yoon),한인권(In Kwon Han) 대한폐경학회 2000 대한폐경학회지 Vol.6 No.1
N/A Background; Rate of bone loss should be increased after menopause and then formation coupled with resoprtion also be increased. Alendronate (Fosamax ;MSD, Rahway, NJ, USA), an antiresorptive drug known to be helpful to prevent bone loss. Alendronate is one of antiresorptive drug for treatment of osteoporosis and resulted in a decrease of bone turnover, There are no available data about Korean people, So, we wanted to determine the effects of alendronate in Korean postmenopausal osteoporosis patients after 1- year treatment Subjects and Methods; We studied 42 women with postmenopausal osteoporosis (bone mineral density[BMD] T score<2.5) who visited osteoporosis clinic in Samsung Cheil Hospital from Jan. 1999 to Apr. 2000, Subjects were stratified in 2 groups. Group 1 treated with alendronate 10mg/day and estrogen, and Group 2 treated with estrogen alone. BMD at the lumbar spine were measured at baseline and 1-year after treatment. We also measured serum marker of bone formation (total alkaline phosphatase[Alk]), and marker of bone resorption (deoxypyridinoline [DPYD]) from urine at baseline, 3months and I-year after treatment. Results; The mean differences in changes of markers after 3 months and 1 year of treatment were remarked significantly (3-Month; delta Alk:-28,7±3.6%, delta DPYD:-31.0±5,4% vs 1-Year; delta Alk:-32.2±3.1%, delta DPYD:-23.0±3.5%). Markers of bone metabolism showed no significant responses between two groups at 3 months and 1year after treatment, Also, Bone mineral density at lumbar spine was significantly increased in Group treated with alendronatc and estrogen than estrogen only group (9.6±0,7% vs 5.3±0.6%, P<0,001). Conclusion; Our data showed that using alendronate with estrogen to the patients of Korean women with osteoporosis increase bone mineral density more, So, we concluded that alendronate therapy with estrogen was helpful to manage postmenopausal osteoporosis patients.
폐경 여성의 골밀도 변화를 중심으로 한 치료 방법의 비용효과적 비교
오한진 ( Han Jin Oh ),김의현 ( Ui Hyun Kim ),오장균 ( Jang Kyun Oh ),윤현구 ( Hyun Koo Yoon ),한인권 ( In Kwon Han ) 대한폐경학회 2001 대한폐경학회지 Vol.7 No.1
N/A Background : There were many strategies to treat postmenopausal women with osteoporosis. Because of bone mass measurement confirms the existence of osteoporosis and also predicts the risk of fracture, the effectiveness of the treatment should be measured by the amount of increased bone mass. Methods : 311 postmenopausal Korean women were evaluated who visited one of university hospital located in Seoul from Aug. 1997 to July 2000, with respect to markers of bone turnover and BMD at lumbar spine. Subjects were classified into 3 groups, peri-menopause, early-menopause, and late-menopause by menopausal states. To evaluate the cost-effectiveness of treatment, we compared changes of BMD after 1-year of treatment and total drug costs for 1-year among 3 groups. And also to evaluated the cost-effectiveness between groups classified by WHO criteria, we also compared changes of BMD and total drug costs after 1-year. Results : Our results showed those findings: 1. The const-effectiveness was similar among 3 groups classified by the menopausal state. 2. Among three groups classified by bone density, osteopenia group showed significantly favorable cost-effectiveness score than normal or osteoporotic group.
한국 폐경 여성에서 이중에너지 방사선 흡수 계측기 ( DEXA ) 의 요추 및 대퇴골 골밀도 표준화
최규홍(Kyu Hong Choi),한인권(In Kwon Han) 대한폐경학회 2000 대한폐경학회지 Vol.6 No.1
N/A Objectives: Bone densitometry is a current method for evaluating skeletal status, assessing osteoporosis, and determining fracture risk. DEXA has rapidly became a dominant method for evaluating skeletal status, But the comparison of patient data among different DHXA scanners is complicated because the instruments show differences in scanner design, bone mineral calibration, and analysis algorithms, and scan site. This study was performed to establish appropriate cross-calibration parameters at the lumbar and femoral sites among two models of DEXA system from different manufacturers. Materials and Methods: In our study, 63 healthy, Korean women aged 37-81 years(mean age:57.1+7,03) were examined, Posteroanterior Lumbar spine (L2-L4) and hip measurements were obtained on a Hologic QDR 4500, and a Noland XR-36 densitometer. All subjects had no spinal deformities, osteophytes, fractures and scoliosis, bilateral hip replacements, and other conditions that could affect BMD measurements. We performed the measurement of BMD in each subject with different two scanners at two scan sites at the same time, Results: The correlations of the patients' spinal BMD(r 0.971) and femoral neck BMD(r 0.905) were excellent for each of the two scanner pairs. From the linear regression analysis of the patient data, cross calibration equations for spinal and femoral neck BMD values were derived, The BMD values at the lumbar spine and proximal femur measured using different scanner showed different proportion of diagnostic criteria in osteoporosis. Conclusion: Even though it has some limitations, the standardization approach as performed in our study may provide compatibility of DEXA results obtained on different scanners
NIDDM 환자에서 혈당조절 전후의 Nitrogen Balance 와 IGF - I 변화에 관한 연구
최웅환(Woong Hwan Choi),박원근(Won Kun Park),신현호(Hyun Ho Shin),한인권(In Kwon Han),김은주,김선우(Sun Woo Kim),최영길(Young Kil Choi) 대한내과학회 1987 대한내과학회지 Vol.34 No.1
N/A We studied the effect of blood sugar control in patients with NIDDM on the IGF-I level and nitrogen balance as a metabolic index. The result as follows 1) There was no difference in IGF-I level between patients with NIDDM and normal control group. (222±60ng/ml vs 221±49ng/ml, p>0.1) 2) There was a statistically significant increment in IGF-I level in the NIDDM patients who improved to positive nitrogen balance from negative nitrogen balance. (217±55ng/ml vs 285±44ng/ml, p<0.05) 3) IGF-I level was not increased in patients who did not improve to positive nitrogen balance after suger control and the patient who was prositive nitrogen blance initially. (231±63ng/m1 vs 190±52ng/ml, p>0.1) 4) IGF-I level was not increased in spite of improved nitrogen balance after sugar control in patients with under body weight. (221±68ng/ml vs 213±42ng/ml, p>0.1) These reult sugested that mornitoring of serum IGF-I level in NIDDM patients is useful marker which represent metabolic compensation with treatment of diabetes.